CLL Videos

Videos

Long-Term Outcomes of CAR T-Cell Therapy for Patients With Relapsed/Refractory CLL

06/21/2023

At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Sponsored

Videos

Chronic Lymphocytic Leukemia: A Review of Unmet Needs in Prognostic Biomarker Testing

06/07/2023

M. Yair Levy, MD, Texas Oncology, discusses the importance of biomarker testing for patients with CLL, reviews unmet needs in prognostic biomarker testing and selection of therapies, and outlines clinical practice guidelines for high-risk...

M. Yair Levy, MD, Texas...

06/07/2023

Oncology

Videos

Treating a Patient With Unmutated IGHV, ATM-Deleted Chronic Lymphocytic Leukemia

03/27/2023

Talha Munir, MD, St. James's Hospital in Leeds, United Kingdom, highlights his treatment choices for the case of a 76-year-old patient with chronic lymphocytic leukemia.

Talha Munir, MD, St. James's...

03/27/2023

Oncology

Videos

Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL

01/26/2023

Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.

Talha Munir, MD, discusses...

01/26/2023

Oncology

Videos

Ibrutinib Plus Venetoclax Induces High Rates of MRD Negativity in IGHV-Unmutated CLL

01/16/2023

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Talha Munir, MD, discusses...

01/16/2023

Oncology

Videos

Role of Minimal Residual Disease in the Management of CLL: How Do We Use it and When?

11/15/2022

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Othman Al-Sawaf, MD, provides...

11/15/2022

Oncology

Videos

BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL

11/14/2022

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in...

11/14/2022

Oncology

Videos

New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors

11/14/2022

Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.

Jan Burger, MD, discusses...

11/14/2022

Oncology

Anthony Mato, MD, PhD, Memorial Sloan Kettering Cancer Center

Videos

Impact of Venetoclax Discontinuation or Modification on Survival Outcomes Among Patients With CLL

06/28/2022

Anthony Mato, MD, PhD, highlights findings from a post-hoc analysis of the phase 3 MURANO trial, which explored the impact of venetoclax dose modification and early discontinuation on survival outcomes for patients with CLL.

Anthony Mato, MD, PhD,...

06/28/2022

Oncology

Andrew Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Videos

Zanubrutinib Plus Obinutuzumab and Venetoclax With MRD-Driven Discontinuation Shows Promise in CLL/SLL

05/14/2022

Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.

Andrew Zelenetz, MD, PhD,...

05/14/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology